Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature 2025-12-18 08:00
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets 2025-12-18 00:00
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics 2025-12-17 21:00
111, Inc. Announces Third Quarter 2025 Unaudited Financial Results 2025-12-17 14:00
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development 2025-12-16 21:30
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer 2025-12-16 18:59
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases 2025-12-16 12:55
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi) 2025-12-15 22:30
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease 2025-12-15 18:00
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. 2025-12-15 14:06
/DISREGARD RELEASE: Ractigen Therapeutics/ 2025-12-12 23:10
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits 2025-12-12 22:00
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy 2025-12-12 21:35
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD) 2025-12-12 20:00
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab 2025-12-12 10:31
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity 2025-12-12 08:00
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial 2025-12-12 04:49
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 2025-12-11 21:00
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases 2025-12-11 14:00
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025 2025-12-11 09:53
1 2 3 4 5 202